← Back to Search
Human Enteric Microsomal CYP4F Enzymes O-Demethylate The Antiparasitic Prodrug Pafuramidine
M. Z. Wang, J. Q. Wu, A. S. Bridges, D. Zeldin, S. Kornbluth, R. Tidwell, J. Hall, M. Paine
Published 2007 · Biology, Medicine
Download PDFAnalyze on Scholarcy
CYP4F enzymes, including CYP4F2 and CYP4F3B, were recently shown to be the major enzymes catalyzing the initial oxidative O-demethylation of the antiparasitic prodrug pafuramidine (DB289) by human liver microsomes. As suggested by a low oral bioavailability, DB289 could undergo first-pass biotransformation in the intestine, as well as in the liver. Using human intestinal microsomes (HIM), we characterized the enteric enzymes that catalyze the initial O-demethylation of DB289 to the intermediate metabolite, M1. M1 formation in HIM was catalyzed by cytochrome P450 (P450) enzymes, as evidenced by potent inhibition by 1-aminobenzotriazole and the requirement for NADPH. Apparent Km and Vmax values ranged from 0.6 to 2.4 μM and from 0.02 to 0.89 nmol/min/mg protein, respectively (n = 9). Of the P450 chemical inhibitors evaluated, ketoconazole was the most potent, inhibiting M1 formation by 66%. Two inhibitors of P450-mediated arachidonic acid metabolism, HET0016 (N-hydroxy-N′-(4-n-butyl-2-methylphenyl)formamidine) and 17-octadecynoic acid, inhibited M1 formation in a concentration-dependent manner (up to 95%). Immunoinhibition with an antibody raised against CYP4F2 showed concentration-dependent inhibition of M1 formation (up to 92%), whereas antibodies against CYP3A4/5 and CYP2J2 had negligible to modest effects. M1 formation rates correlated strongly with arachidonic acid ω-hydroxylation rates (r2 = 0.94, P < 0.0001, n = 12) in a panel of HIM that lacked detectable CYP4A11 protein expression. Quantitative Western blot analysis revealed appreciable CYP4F expression in these HIM, with a mean (range) of 7 (3-18) pmol/mg protein. We conclude that enteric CYP4F enzymes could play a role in the first-pass biotransformation of DB289 and other xenobiotics.
This paper references
Cooperativity in oxidations catalyzed by cytochrome P450 3A4.
Y. Ueng (1997)
Enhancement of Cardiac L-Type Ca2+ Currents in Transgenic Mice with Cardiac-Specific Overexpression of CYP2J2
Y. Xiao (2004)
Activation of CYP 3 A 4 : evidence for the simultaneous binding of two substrates in a cytochrome P 450 active site
M Shou (1994)
Metabolites of an orally active antimicrobial prodrug, 2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime, identified by liquid chromatography/tandem mass spectrometry.
Lian Zhou (2004)
Development of Pentamidine Analogues as New Agents for the Treatment of Pneumocystis carinii Pneumonia a
R. Tidwell (1990)
Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation.
D. Kroetz (2005)
Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11.
P. Powell (1998)
20-HETE contributes to the acute fall in cerebral blood flow after subarachnoid hemorrhage in the rat.
F. Kehl (2002)
cDNA cloning and expression of a novel cytochrome p450 (cyp4f12) from human small intestine.
T. Hashizume (2001)
THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
M. Paine (2006)
Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site.
M. Shou (1994)
Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism.
A. Kalsotra (2006)
Anti-pneumocystis activity of bis-amidoximes and bis-o-alkylamidoximes prodrugs
D. Boykin (1996)
REGULATION AND INHIBITION OF ARACHIDONIC ACID ω-HYDROXYLASES AND 20-HETE FORMATION
D. Kroetz (2005)
Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.
R. Obach (1997)
Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible.
D. Stresser (2004)
Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes.
T. Hashizume (2002)
Catalytic Activity and Isoform-Specific Inhibition of Rat Cytochrome P450 4F Enzymes
F. Xu (2004)
Human African trypanosomiasis: pharmacological re‐engagement with a neglected disease
M. Barrett (2007)
Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors.
X. Nguyen (1999)
Cloning of CYP2J2 gene and identification of functional polymorphisms.
Lorraine M. King (2002)
Enhanced Permeability of the Antimicrobial Agent 2,5-Bis(4-Amidinophenyl)Furan Across Caco-2 Cell Monolayers Via Its Methylamidoxime Prodrug
Lian Zhou (2004)
Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(Nmethoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug
I Midgley (2007)
Pharmacokinetics and Metabolism of the Prodrug DB289 (2,5-Bis[4-(N-methoxyamidino)phenyl]furan Monomaleate) in Rat and Monkey and Its Conversion to the Antiprotozoal/Antifungal Drug DB75 (2,5-Bis(4-guanylphenyl)furan Dihydrochloride)
I. Midgley (2007)
Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans.
B. P. Das (1977)
Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole.
M. Paine (1999)
Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis.
C. Bell (1990)
Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase.
D. Zeldin (1993)
Diamidines as antitrypanosomal, antileishmanial and antimalarial agents.
K. Werbovetz (2006)
Alternative splicing determines the function of CYP4F3 by switching substrate specificity.
P. Christmas (2001)
UNUSUAL DEHYDROXYLATION OF ANTIMICROBIAL AMIDOXIME PRODRUGS BY CYTOCHROME b5 AND NADH CYTOCHROME b5 REDUCTASE
Janelle Y Saulter (2005)
Human trypanosomiasis in the Ivory Coast: therapy and problems.
F. Doua (1993)
CYP4F Enzymes Are the Major Enzymes in Human Liver Microsomes That Catalyze the O-Demethylation of the Antiparasitic Prodrug DB289 [2,5-Bis(4-amidinophenyl)furan-bis-O-methylamidoxime]
M. Z. Wang (2006)
Differential Mechanisms of Cytochrome P450 Inhibition and Activation by α-Naphthoflavone*
A. P. Koley (1997)
This paper is referenced by
New Drugs for Human African Trypanosomiasis: A Twenty First Century Success Story
Emily A Dickie (2020)
A New Marmoset P450 4F12 Enzyme Expressed in Small Intestines and Livers Efficiently Metabolizes Antihistaminic Drug Ebastine
S. Uehara (2016)
Isolation and identification of intestinal CYP3A inhibitors from cranberry (Vaccinium macrocarpon) using human intestinal microsomes.
Eunkyung Kim (2011)
Evaluation of CYP2D6 Protein Expression and Activity in the Small Intestine to Determine Its Metabolic Capability in the Japanese Population.
Momoko Kawakami (2017)
Biochemistry and Occurrence of O-Demethylation in Plant Metabolism
J. Hagel (2010)
Identification of a Cranberry Juice Product that Inhibits Enteric CYP3A-Mediated First-Pass Metabolism in Humans
N. Ngo (2009)
Reduktion N-oxygenierter Verbindungen durch die mitochondriale Amidoxim Reduzierende Komponente (mARC)
Danilo Froriep (2013)
Translational methods for quantitative prediction of metabolic herbal product-drug interactions: case study with milk thistle
Scott J. Brantley (2013)
10.05 – Metabolic Barrier of the Gastrointestinal Tract*
K. Wolf (2010)
Effects of parasitic infection on the pharmacokinetics and disposition of pentamidine analogs
Claudia N Generaux (2010)
Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.
H. Nishimuta (2011)
Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine
S. Uehara (2015)
Detection and Mechanistic Comparison of Two Anti- Trypanosomal Diamidines in a Rat Renal Model
R. B. Goldsmith (2011)
Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models
S. Peters (2016)
Determination of Absolute Protein Content of Hepatic CYP4F Enzymes in Human Liver Microsomes Using LC/MS/MS Methodology and Comparison with Immunoquantification and Enzyme Activity
Scott A. Michaels (2013)
Cytochrome P450-activated prodrugs.
P. R. Montellano (2013)
Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1
J. Park (2019)
Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response
J. E. Zhang (2017)
Impact of Organic Solvents on Cytochrome P450 Probe Reactions: Filling the Gap with (S)-Warfarin and Midazolam Hydroxylation
Vanessa González-Pérez (2012)
PharmGKB summary: very important pharmacogene information for CYP4F2
Maria L Alvarellos (2015)
In Vitro and In Vivo Evaluation of 28DAP010, a Novel Diamidine for Treatment of Second-Stage African Sleeping Sickness
T. Wenzler (2014)
Human cytochrome P450 4F3: structure, functions, and prospects
L. Corcos (2012)
Prodrug design for the potent cardiovascular agent Nω-hydroxy-L-arginine (NOHA): synthetic approaches and physicochemical characterization.
D. Schade (2011)
Involvement of CYP4F2 in the Metabolism of a Novel Monophosphate Ester Prodrug of Gemcitabine and Its Interaction Potential In Vitro
Yedong Wang (2018)
CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis
Y. Jin (2011)
A Systematic Approach to Evaluate Herb-Drug Interaction Mechanisms: Investigation of Milk Thistle Extracts and Eight Isolated Constituents as CYP3A Inhibitors
S. Brantley (2013)
Cytochrome P450-activated prodrugs.
P. R. Ortiz de Montellano (2013)
Développement de méthodes analytiques par LC-MS/MS pour la caractérisation de l’activité et de l’expression des CYP450s chez l’humain
Alexia Grangeon (2017)
Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys
S. Uehara (2014)
A Semiphysiologically Based Pharmacokinetic Modeling Approach to Predict the Dose-Exposure Relationship of an Antiparasitic Prodrug/Active Metabolite Pair
Grace Zhixia Yan (2012)
New Prodrugs of the Antiprotozoal Drug Pentamidine
Joscha Kotthaus (2011)
Development and validation of an absolute protein assay for the simultaneous quantification of fourteen CYP450s in human microsomes by HPLC-MS/MS-based targeted proteomics.
Alexia Grangeon (2019)See more